Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Lorlatinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
LORBRENA (lorlatinib) is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).